Cargando…

Maintaining Efficacy But Decreasing Toxicity in the Treatment of Hodgkin Lymphoma

Detalles Bibliográficos
Autor principal:	Ansell, Stephen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2017
Materias:	Invited Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745978/ https://www.ncbi.nlm.nih.gov/pubmed/31723736 http://dx.doi.org/10.1097/HS9.0000000000000007

Ejemplares similares

Recent advances in the management of Hodgkin lymphoma
por: Villasboas, Jose C., et al.
Publicado: (2016)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022)

Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
por: Pei, Fajun, et al.
Publicado: (2021)

Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicity
por: Barrett, Aisling, et al.
Publicado: (2023)

Immunotherapies in Non-Hodgkin’s Lymphoma
por: Bezombes, Christine, et al.
Publicado: (2021)

Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors
por: Joshi, Maansi, et al.
Publicado: (2020)

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
por: Wang, Yucai, et al.
Publicado: (2018)

Managing the toxicities of the FEC-100 followed by docetaxel regimen: The price of success
por: Laing, Kara
Publicado: (2008)

Second cancer risk following Hodgkin lymphoma
por: Sud, Amit, et al.
Publicado: (2017)

Minimising the Toxicities of First Line Hodgkin Lymphoma Treatment in the Modern Era
por: Follows, Annabel M., et al.
Publicado: (2022)

Bringing circulating tumor DNA to the clinic in Hodgkin lymphoma
por: Kurtz, David M.
Publicado: (2021)

PET-guided treatment in advanced-stage Hodgkin lymphoma: yes but which one?
por: Rossi, Cédric, et al.
Publicado: (2019)

Managing advanced stage Hodgkin lymphoma
por: Saikia, TK
Publicado: (2015)

Hodgkin Lymphoma—The Spectrum from Diagnostics to Molecular Science, Movement and Current Treatment Approaches
por: Hartmann, Sylvia
Publicado: (2023)

Peripheral T Cell Non-Hodgkin's Lymphoma following Treatment of Hodgkin's Lymphoma
por: Chang, Sun Hee, et al.
Publicado: (2015)

Progress in understanding the biology of nodular lymphocyte-predominant Hodgkin lymphoma
por: Straus, David J.
Publicado: (2021)

Advances and Clinical Outcomes in Hodgkin Lymphoma in the Era of Novel Therapies
por: Paviglianiti, Annalisa, et al.
Publicado: (2023)

Expanding the bacterial origins of nodular lymphocyte-predominant Hodgkin lymphoma
por: Gandhi, Maher K., et al.
Publicado: (2023)

End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET
por: Chohan, Karan L., et al.
Publicado: (2022)

Pulmonary Toxicity of Hodgkin Lymphoma Treatment: A Prospective Single-Center Study
por: Jona, Adam, et al.
Publicado: (2021)

Expanded neuromuscular morbidity in Hodgkin lymphoma after radiotherapy
por: Oishi, Tatsuya, et al.
Publicado: (2020)

Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
por: Makita, Shinichi, et al.
Publicado: (2020)

T‐Cell Phenotype Is Associated with Decreased Survival in Non‐Hodgkin's Lymphoma
por: Shimizu, Kazuyuki, et al.
Publicado: (1989)

Bleomycin in Hodgkin's Lymphoma – A Boon or a Bane? – A Retrospective Study of Bleomycin Pulmonary Toxicity in Hodgkin's Lymphoma
por: Udupa, Chethana Babu K, et al.
Publicado: (2019)

Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma
por: Porrata, Luis F, et al.
Publicado: (2015)

Pulmonary toxicity induced by bleomycin in a patient with Hodgkin lymphoma
por: Oliveira, CF, et al.
Publicado: (2005)

Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective
por: Villasboas, Jose Caetano, et al.
Publicado: (2016)

Rapid determination of nematode cell and organ susceptibility to toxic treatments
por: Jasmer, Douglas P., et al.
Publicado: (2020)

Leukaemia and non-Hodgkin's lymphoma in children and young adults: are prenatal and neonatal factors important determinants of disease?
por: Roman, E., et al.
Publicado: (1997)

Clinical Management of Long-Term Survivors after Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma
por: Bari, Alessia, et al.
Publicado: (2022)

Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management
por: Boussios, Stergios, et al.
Publicado: (2012)

Preventing treatment delays for benign gynaecological conditions
por: Robinson, Dudley
Publicado: (2022)

Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
por: Fontana, Marianna, et al.
Publicado: (2023)

Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential
por: Toltz, Allison, et al.
Publicado: (2015)

Impact of radiation techniques on lung toxicity in patients with mediastinal Hodgkin’s lymphoma
por: Pepper, Niklas Benedikt, et al.
Publicado: (2020)

Bendamustine in the treatment of non-Hodgkin’s lymphomas
por: Hagemeister, Fredrick, et al.
Publicado: (2009)

Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Hauptrock, Beate, et al.
Publicado: (2008)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

Editorial: Advances in the treatment of Hodgkin lymphoma
por: Mei, Matthew, et al.
Publicado: (2023)

Advances in the treatment of Hodgkin's lymphoma (Review)
por: Che, Yuxuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sh4r1sph4o0imrh08kbc1l646m